Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Director comp.
Notes underwriting agrmnt
|
|
Priveterra Acquisition Corp.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/02/2023 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits Interactive Data |
| 07/27/2023 |
8-K
| Director compensation was amended/approved, Entered into an underwriting agreement for the issuance and sale of notes|
Docs:
|
"THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PRIVETERRA ACQUISITION CORP. Priveterra Acquisition Corp. , a corporation organized and existing under the General Corporation Law of the State of Delaware , does hereby certify as follows: 1.            The name of the Corporation is Priveterra Acquisition Corp. The Corporation was incorporated under the name Priveterra Acquisition Corp. by the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware on November 17, 2020 and is being amended and restated to reflect that the Corporation has changed its name. 2.             An amended and resta...",
"AEON Biopharma, Inc. as of July 21, 2023",
"AEON BIOPHARMA, INC. AMENDED AND RESTATED 2019 INCENTIVE AWARD PLAN Effective July 21, 2023 AEON BIOPHARMA, INC. AMENDED AND RESTATED 2019 INCENTIVE AWARD PLAN 1.             Purposes of the Plan . The purposes of this AEON Biopharma, Inc. Amended and Restated 2019 Incentive Award Plan are to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentives to Employees, Directors and Consultants and to promote the success of the Company’ s business. Options granted under the Plan may be Incentive Stock Options or Non-Qualified Stock Options, as determined by the Administrator at the time of grant. Stock Appreciation Rights, Stock Purchase Rights, Restri...",
"2 subject thereto upon the date of Optionee’s termination. II. AGREEMENT 1. Grant of Option. The Company hereby grants to Optionee an Option to purchase the number of Shares set forth in the Notice of Grant, at the exercise price per Share set forth in the Notice of Grant . Notwithstanding anything to the contrary anywhere else in this Stock Option Agreement, the Option is subject to the terms, definitions and provisions of the Plan adopted by the Company, which is incorporated herein by reference. If designated in the Notice of Grant as an Incentive Stock Option, the Option is intended to qualify as an incentive stock option as defined in Section 422 of the Code; provided, however, that to the extent that the aggregate Fair Market Value of stock with respect to which incentive stock optio...",
"US-DOCS\140721846.3 EXHIBIT A RESTRICTED STOCK UNIT AGREEMENT Capitalized terms not specifically defined in this Restricted Stock Unit Agreement have the meanings specified in the Grant Notice or, if not defined in the Grant Notice, in the Plan. ARTICLE I. GENERAL 1.1 Award of RSUs. The Company has granted the RSUs to Participant effective as of the Grant Date set forth in the Grant Notice . Each RSU represents the right to receive one Share as set forth in this Agreement. Participant will have no right to the distribution of any Shares until the time the RSUs have vested. 1.2 Incorporation of Terms of Plan. The RSUs are subject to the terms and conditions set forth in this Agreement and the Plan, which is incorporated herein by reference. In the event of any inconsistency between the Plan...",
"Cover Page Interactive Data File (embedded within the Inline XBRL document)",
"2 US-DOCS\137441470.5 Restructuring) paid by the Participant for such Shares or not issuing any Shares covered by the Award or Prior Plan Award, the unused Shares covered by the Award or Prior Plan Award will, as applicable, become or again be available for Award grants under the Plan. Further, Shares delivered to the Company by a Participant to satisfy the applicable exercise or purchase price of an Award or Prior Plan Award and/or to satisfy any applicable tax withholding obligation with respect to an Award or Prior Plan Award will, as applicable, become or again be available for Award grants under the Plan. The payment of Dividend Equivalents in cash in conjunction with any outstanding Awards or Prior Plan Awards shall not count against the Overall Share Limit. Notwithstanding anything ...",
"2 US-DOCS\138377375.2 c. Payment of Retainers. The annual cash retainers described in Sections 1 and 1 shall be earned on a quarterly basis based on a calendar quarter and shall be paid by the Company in arrears not later than 30 days following the end of each calendar quarter. In the event an Eligible Director does not serve as a director, or in the applicable positions described in Section 1, for an entire calendar quarter, the retainer paid to such Eligible Director shall be prorated for the portion of such calendar quarter actually served as a director, or in such position, as applicable. 2. Equity Compensation. a. General. Eligible Directors shall be granted the equity awards described below. The awards described below shall be granted under and shall be subject to the terms and provi...",
"EXHIBI 10.11",
"EMPLOYMENT AGREEMENT" |
|
| 07/24/2023 |
8-K
| Quarterly results |
| 07/17/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure...|
Docs:
|
"Priveterra Acquisition Corp. Announces Authorization to List on NYSE Upon Completion of Business Combination with AEON Biopharma, Inc. FORT LAUDERDALE, FL- July 17, 2023- Priveterra Acquisition Corp. and following its name change to AEON Biopharma, Inc., “New AEON”) today announced that NYSE Regulation, on July 13, 2023, authorized New AEON common stock and New AEON warrants to be listed on NYSE American LLC upon the Business Combination with AEON Biopharma, Inc., following which AEON will be a wholly owned subsidiary of Priveterra and Priveterra will change its name to AEON Biopharma, Inc. Trading is expected to begin on NYSE on July 24, 2023, under the new ticker symbol “AEON” for the New AEON Common Stock following the consummation of the Business Combination, which is expected to occu..." |
|
| 07/11/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure...|
Docs:
|
"Priveterra Acquisition Corp. Announces Intention to Transfer to NYSE Upon Completion of Business Combination with AEON Biopharma, Inc. FORT LAUDERDALE, FL- July 11, 2023- Priveterra Acquisition Corp. and following its name change to AEON Biopharma, Inc., “New AEON”) today announced that, upon the Business Combination with AEON Biopharma, Inc, following which AEON will be a wholly owned subsidiary of Priveterra and Priveterra will change its name to AEON Biopharma, Inc., New AEON Common Stock will be listed on NYSE American LLC . The decision to list on NYSE was made in connection with the Business Combination and enables the combined company to be listed alongside other innovative companies that are also listed on NYSE. Trading is expected to begin on NYSE on or about July 24, 2023, under..." |
|
| 07/05/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/30/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 06/28/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 06/15/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ... |
| 06/08/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/23/2023 |
8-K
| Investor presentation |
| 05/01/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data|
Docs:
|
"AMENDMENT NO. 1 to BUSINESS COMBINATION AGREEMENT",
"AMENDMENT NO. 1 to SPONSOR SUPPORT AGREEMENT",
"PROMISSORY NOTE Principal Amount: $1,000,000 Dated as of April 27, 2023 PRIVETERRA Acquisition Corp., a Delaware corporation , promises to pay to the order of Priveterra Sponsor, LLC or its registered assigns or successors in interest , or order, the principal sum of One Million Dollars or such lesser amount as shall have been advanced by Payee to Maker and shall remain unpaid under this Note on the Maturity Date in lawful money of the United States of America, on the terms and conditions described below. All payments on this Note shall be made by check or wire transfer of immediately available funds or as otherwise determined by the Maker to such account as the Payee may from time to time designate by written notice in accordance with the provisions of this Note. 1. Principal. The entire ..." |
|
| 04/05/2023 |
8-K
| Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review  ... |
| 02/24/2023 |
8-K
| Investor presentation |
| 02/10/2023 |
8-K
| Quarterly results |
| 02/06/2023 |
8-K
| Quarterly results |
| 01/11/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 01/10/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data|
Docs:
|
"AEON Biopharma and Priveterra Acquisition Corp. Announce Additional Capital Commitment from Existing Investors for at Least $20 Million IRVINE, Calif., January 10, 2023 – AEON Biopharma, Inc. , a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, and Priveterra Acquisition Corp. , a special purpose acquisition company, today announced that at least $20 million in additional funding has been committed by existing AEON investors. The commitments have been delivered in connection with the proposed business combination between AEON and Priveterra announced on December 13, 2022, and represent nearly half of the minimum cash requirement for the proposed transaction. The terms of the c..." |
|
| 12/13/2022 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte...|
Docs:
|
"Execution Version BUSINESS COMBINATION AGREEMENT BY AND AMONG Priveterra Acquisition Corp., PRIVETERRA MERGER SUB, INC. AND AEON Biopharma, INC. DATED AS OF DECEMBER 12, 2022",
"AEON Biopharma to Become Publicly Listed via Merger with Priveterra Acquisition Corp.; Accelerating Clinical Development of ABP-450 Injection to Treat Debilitating Medical Conditions in Neurology",
"2 DisclaimerAbout This PresentationThis investor presentation does not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed Business Combination or an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any security of Priveterra, the Company, or any of their respective affiliates. No such offering of securities shall be made except by means of a prospectus meeting the requirements of section 10 of the Securities Act of 1933, as amended.Forward Looking StatementsCertain statements, estimates, targets and projections in this Presentation may be considered forward-looking statements. Forward-looking statements generally relate to future events or involving, or future performance of, Priveterr..." |
|
| 08/19/2022 |
8-K
| Quarterly results |
| 02/25/2022 |
8-K
| Quarterly results |
| 06/29/2021 |
8-K
| Quarterly results |
| 06/04/2021 |
8-K
| Quarterly results |
| 03/25/2021 |
8-K
| Quarterly results |
| 02/18/2021 |
8-K
| Quarterly results |
| 02/12/2021 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Departure of Directors or Certain Office...|
Docs:
|
"Underwriting Agreement, by and among the Company and Wells Fargo Securities, LLC and Guggenheim Securities, LLC, as representatives of the several underwriters",
"Second Amended and Restated Certificate of Incorporation",
"Warrant Agreement, by and between the Company and Continental Stock Transfer & Trust Company, as warrant agent",
"Letter Agreement, by and among the Company, its executive officers, its directors and Priveterra Sponsor, LLC",
"Investment Management Trust Agreement, by and between the Company and Continental Stock Transfer & Trust Company, as trustee",
"Registration Rights Agreement, by and among the Company, Priveterra Sponsor, LLC and the other holders party thereto",
"Private Placement Warrants Purchase Agreement, by and among the Company and Priveterra Sponsor, LLC",
"Administrative Services Agreement, by and between the Company and Priveterra Sponsor, LLC",
"Chief Legal Officer and Secretary",
"Chief Legal Officer and Secretary" |
|
|
|